Clinical trialNCT04665921TerminatedPhase 1Interventional

A Study of SGN-STNV in Advanced Solid Tumors

SponsorSeagen Inc.Enrollment111Appendiceal AdenocarcinomaCarcinoma, Non-Small Cell LungColorectal NeoplasmsEndometrial NeoplasmsEsophageal NeoplasmsExocrine Pancreatic Adenocarcinoma+6 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Suzanne McGoldrick, MD
Seagen Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University of Ottawa / Ottawa General Hospital
Ottawa, Ontario, Canada
University Health Network, Princess Margaret Hospital
Toronto, Other, Canada

France

Institut Gustave Roussy
Villejuif, Other, France

Italy

Istituto Europeo Di Oncologia
Milan, Other, Italy

Spain

Hospital Universitari Vall D'Hebron
Barcelona, Other, Spain

United Kingdom

the Royal Marsden Hospital (surrey)
Sutton, Other, United Kingdom

United States

the Angeles Clinic and Research Institute
Los Angeles, California, United States
University of California, San Francisco | Hdfccc - Hematopoietic Malignancies
San Francisco, California, United States
Shands Cancer Center / University of Florida
Gainesville, Florida, United States
University of Miami
Miami, Florida, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
South Texas Accelerated Research Therapeutics Midwest
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
Magee Womens Hospital of Upmc
Pittsburgh, Pennsylvania, United States
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SGN-STNV

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Jan 2021
Primary completion: 1 Mar 2024
Completion: 1 Mar 2024
Last update posted: 7 Feb 2025
Registered enrollment: 111
Registry id: NCT04665921

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.